{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-026295","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.586241+00:00","generated_at":"2026-06-01T06:44:10.021703+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cardiff Oncology rescinds 1.7M options, regrants same subject to stockholder approval","bullets":["Board rescinded 1,697,712 options granted on March 7, 2024 at $3.51/share.","Board regranted 1,697,712 options at same $3.51 strike, contingent on June 20, 2024 stockholder vote.","Stockholder approval required to increase shares available under 2021 Equity Incentive Plan.","Bylaw amended to align voting standards: plurality for directors, majority for other matters."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-026295","json":"https://secwatch.observer/filing/0001628280-24-026295.json","markdown":"https://secwatch.observer/filing/0001628280-24-026295.md","text":"https://secwatch.observer/filing/0001628280-24-026295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024026295/0001628280-24-026295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024026295/crdf-20240530.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:44:10.021703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}